NCT00427908View on ClinicalTrials.gov

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

PHASE2CompletedINTERVENTIONAL
Enrollment

613

Participants

Timeline

Start Date

February 7, 2007

Primary Completion Date

December 3, 2007

Study Completion Date

December 3, 2007

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)

One intramuscular dose.

BIOLOGICAL

Mencevax™ ACWY

One subcutaneous dose.

BIOLOGICAL

Meningitec™

One intramuscular dose.

Trial Locations (11)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28100

GSK Investigational Site, Pori

33100

GSK Investigational Site, Tampere

90100

GSK Investigational Site, Oulu

02100

GSK Investigational Site, Espoo

00100

GSK Investigational Site, Helsinki

00930

GSK Investigational Site, Helsinki

04400

GSK Investigational Site, Järvenpää

01300

GSK Investigational Site, Vantaa

01600

GSK Investigational Site, Vantaa

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY